Cedric Pobel, MD

Cedric Pobel, MD, discusses how the results of the PEACE-1 trial support the use of radiotherapy plus standard of care and abiraterone in low-volume metastatic castration-sensitive prostate cancer.

Cedric Pobel, MD, covers the PEACE-1 trial of radiotherapy, standard of care, and abiraterone in low-volume metastatic castration-sensitive prostate cancer.

Cedric Pobel, MD, discusses the design and objectives of the phase 3 PEACE-1 trial for patients with de novo metastatic castration-sensitive prostate cancer.